---
figid: PMC12009697__fonc-15-1527484-g002
figtitle: Activation of MAPK and PI3K/MTOR signaling pathways by oncogenic FGFR2 fusion
  protein
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12009697
filename: fonc-15-1527484-g002.jpg
figlink: /pmc/articles/PMC12009697/figure/F2/
number: F2
caption: Activation of MAPK and PI3K/MTOR signaling pathways by oncogenic FGFR2 fusion
  protein. Upon inhibition of FGFR2 signaling by Lenvatinib and Infigratinib in this
  case of iCCA an activating PIK3CA (p110α) mutation (marked with an asterisk) was
  detected, which leads to an aberrant activation of downstream signaling pathway
  (red arrows). p110α can be targeted by Alpelisib. Alternatively, Gedatolisib, a
  pan-PI3K and dual mTOR inhibitor, or Sapanisertib, a dual mTOR inhibitor, could
  be used for targeted therapy. Created with BioRender.com
papertitle: 'Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an
  intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion'
reftext: Nadja Ballin, et al. Front Oncol. 2025;15(NA).
year: '2025'
doi: 10.3389/fonc.2025.1527484
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media SA
keywords: FGFR inhibition | secondary resistance | PIK3CA | intrahepatic cholangiocarcinoma
  (iCCA) | molecular tumor board | CDKN2A/B
automl_pathway: 0.9410981
figid_alias: PMC12009697__F2
figtype: Figure
redirect_from: /figures/PMC12009697__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12009697__fonc-15-1527484-g002.html
  '@type': Dataset
  description: Activation of MAPK and PI3K/MTOR signaling pathways by oncogenic FGFR2
    fusion protein. Upon inhibition of FGFR2 signaling by Lenvatinib and Infigratinib
    in this case of iCCA an activating PIK3CA (p110α) mutation (marked with an asterisk)
    was detected, which leads to an aberrant activation of downstream signaling pathway
    (red arrows). p110α can be targeted by Alpelisib. Alternatively, Gedatolisib,
    a pan-PI3K and dual mTOR inhibitor, or Sapanisertib, a dual mTOR inhibitor, could
    be used for targeted therapy. Created with BioRender.com
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FRS2
  - GRB2
  - GAB1
  - PIGU
  - XYLT2
  - SOS1
  - SOS2
  - NF1
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - PDK1
  - PDPK1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - TSC1
  - CCL26
  - TSC2
  - EPHB2
  - MAPK1
  - MAPK3
  - RHEB
  - RHEBP1
  - RPTOR
  - Lenvatinib
  - RAS
  - MEK
  - Sapanisertib
---
